Short-lived Options
Cardiovascular disease – CVD
Chronic kidney disease – CKD
Growing prevalence due to CVD
(diabetes, hypertension, obesity)
Accounting for more deaths than breast and prostate cancers combined
Patients who need cardiovascular replacements suffer repeated procedures, complications or take long-term medication, because current treatment options have severe limitations.
This is especially evident in patients who need:
Natural cardiovascular restoration
Xeltis’ devices naturally evolve into living blood vessels or heart valves, when colonized by patient’s own tissue.
This therapeutic process is called Endogenous Tissue Restoration, or ETR.
Xeltis’ restorative technology is the world’s most advanced polymer-based technology platform for cardiovascular restoration – through ETR.
ETR
Endogenous Tissue Restoration (ETR) is a new therapeutic approach, enabling the patient’s own body to naturally restore a new blood vessel or heart valve.
With ETR, the patient’s natural healing system develops tissue that pervades Xeltis’ device, forming a new, natural and fully functional blood vessel or heart valve within it. As ETR occurs, Xeltis implants are gradually absorbed by the body.
ETR is enabled by bioabsorbable polymers based on Nobel Prize awarded science.
ETR In Action
01
Xeltis devices work as normal heart valves or blood vessels once implanted.
02
New tissue forms around and inside the device to develop a new, living, heart valve or blood vessel.
03
Xeltis devices absorb over time, leaving patients with a natural, healthy and functioning heart valve or blood vessel.
